NEUE Quote, Financials, Valuation and Earnings

The Cigna Group has a net margin of -24.65% compared to NeueHealth's net margin of 1.18%. NeueHealth's return on equity of -3241.93% beat The Cigna Group's return on equity of 6.99%.

NeueHealth has a consensus price target of --, signalling upside risk potential of 83.25%. On the other hand The Cigna Group has an analysts' consensus of $396.77 which suggests that it could grow by 43.28%. Given that NeueHealth has higher upside potential than The Cigna Group, analysts believe NeueHealth is more attractive than The Cigna Group.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cigna Group has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.631%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cigna Group offers a yield of 2.02% to investors and pays a quarterly dividend of $1.40 per share. NeueHealth pays -- of its earnings as a dividend. The Cigna Group pays out 28.08% of its earnings as a dividend. The Cigna Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

NeueHealth quarterly revenues are $232.9M, which are smaller than The Cigna Group quarterly revenues of $62.8B. NeueHealth's net income of -$57.4M is lower than The Cigna Group's net income of $739M. Notably, NeueHealth's price-to-earnings ratio is -- while The Cigna Group's PE ratio is 26.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.03x versus 0.35x for The Cigna Group. Usually stocks with elevated PS ratios are considered overvalued.

Clover Health Investments has a net margin of -24.65% compared to NeueHealth's net margin of -2.77%. NeueHealth's return on equity of -3241.93% beat Clover Health Investments's return on equity of -29.15%.

NeueHealth has a consensus price target of --, signalling upside risk potential of 83.25%. On the other hand Clover Health Investments has an analysts' consensus of $4.68 which suggests that it could grow by 44.74%. Given that NeueHealth has higher upside potential than Clover Health Investments, analysts believe NeueHealth is more attractive than Clover Health Investments.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Clover Health Investments has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $232.9M, which are smaller than Clover Health Investments quarterly revenues of $331M. NeueHealth's net income of -$57.4M is lower than Clover Health Investments's net income of -$9.2M. Notably, NeueHealth's price-to-earnings ratio is -- while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.03x versus 0.78x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

Centene has a net margin of -24.65% compared to NeueHealth's net margin of 1.7%. NeueHealth's return on equity of -3241.93% beat Centene's return on equity of 11.5%.

NeueHealth has a consensus price target of --, signalling upside risk potential of 83.25%. On the other hand Centene has an analysts' consensus of $79.39 which suggests that it could grow by 33.25%. Given that NeueHealth has higher upside potential than Centene, analysts believe NeueHealth is more attractive than Centene.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centene has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.321%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $232.9M, which are smaller than Centene quarterly revenues of $42B. NeueHealth's net income of -$57.4M is lower than Centene's net income of $713M. Notably, NeueHealth's price-to-earnings ratio is -- while Centene's PE ratio is 10.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.03x versus 0.20x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -24.65% compared to NeueHealth's net margin of -2.25%. NeueHealth's return on equity of -3241.93% beat Oscar Health's return on equity of 2.86%.

NeueHealth has a consensus price target of --, signalling upside risk potential of 83.25%. On the other hand Oscar Health has an analysts' consensus of $19.00 which suggests that it could grow by 37.38%. Given that NeueHealth has higher upside potential than Oscar Health, analysts believe NeueHealth is more attractive than Oscar Health.

NeueHealth has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeueHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeueHealth pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

NeueHealth quarterly revenues are $232.9M, which are smaller than Oscar Health quarterly revenues of $2.4B. NeueHealth's net income of -$57.4M is lower than Oscar Health's net income of -$54.6M. Notably, NeueHealth's price-to-earnings ratio is -- while Oscar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeueHealth is 0.03x versus 0.46x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.